ATC12

ATC12 (1.56-100 μM; 10 min) disrupts the interaction between purified Aurora-A^KDCM and the TPX2_1-43 peptide in vitro, with an IC₅₀ of 25.6 μM^[1].
ATC12 (10 μM; 24 h) reduces the formation of the Aurora-A/TPX2 complex on the mitotic spindle and the level of pT288 Aurora-A at spindle poles in U2OS osteosarcoma cells^[1].
ATC12 (10 μM; 24 h) disrupts the formation of Aurora-A/TPX2 complexes in mitotic and interphase nuclei of MCF7 and MDA-MB-231 breast cancer cells, and reduces the nuclear level of Aurora-A^[1].
ATC12 (30-50 μM; 0-48 h) inhibits the proliferation of MCF7 breast cancer cells, prolongs the mitotic process, reduces the cell growth rate, and induces apoptotic cell death^[1].
ATC12 (30-50 μM; 0-72 h) inhibits the proliferation of MDA-MB-231 breast cancer cells, prolongs mitotic duration, reduces cell growth rate and induces cellular senescence without triggering cell death^[1].
ATC12 (10-100 μM; 5 days) reduces the viability of patient-derived organoids BCO-21, BCO-46 and BCO-61 from triple-negative breast cancer (TNBC) in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.